$IMVT
Immunovant, Inc. Stock $imvt

$imvt Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000176401321000052 Filed on June 01, 2021

Income Statement

Concept	2021	2020 Q1	2020
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$39.51M	$6.320M	$18.15M
YoY Change	117.69%
% of Gross Profit
Research & Development	$68.60M	$14.17M	$47.93M
YoY Change	43.14%		86.25%
% of Gross Profit
Depreciation & Amortization	$65.00K	$0.00	$21.00K
YoY Change	209.52%		110.0%
% of Gross Profit
Operating Expenses	$108.1M	$20.48M	$66.08M
YoY Change	63.62%		132.46%
Operating Profit
YoY Change
Interest Expense	$0.00	$0.00	$625.0K
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	$328.0K	-$130.0K	$412.0K
YoY Change	-20.39%		-365.81%
Pretax Income	-$107.8M	-$20.61M	-$66.29M
YoY Change	62.6%		131.95%
Income Tax	-$358.0K	-$60.00K	$97.00K
% Of Pretax Income
Net Earnings	-$107.4M	-$20.55M	-$66.39M
YoY Change	61.82%		132.13%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.22
Diluted Earnings Per Share	-$1.22	-$376.6K	-$1.537M
COMMON SHARES
Basic Shares Outstanding	87.76M shares	56.46M
Diluted Shares Outstanding	87.76M shares

Balance Sheet

Concept	2021	2020 Q1	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$400.1M	$100.6M	$100.6M
YoY Change	297.71%	100500.0%
Cash & Equivalents		$100.6M
Short-Term Investments
Other Short-Term Assets	$8.300M	$5.500M	$5.500M
YoY Change	50.91%	2650.0%
Inventory
Prepaid Expenses		$5.460M
Receivables
Other Receivables
Total Short-Term Assets	$409.0M	$109.1M	$109.1M
YoY Change	274.89%	767.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.500M	$65.00K	$100.0K
YoY Change	3400.0%	20.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$200.0K	$200.0K
YoY Change	-100.0%
Total Long-Term Assets	$3.500M	$311.0K	$300.0K
YoY Change	1066.67%	-75.1%
TOTAL ASSETS
Total Short-Term Assets	$409.0M	$109.1M	$109.1M
Total Long-Term Assets	$3.500M	$311.0K	$300.0K
Total Assets	$412.5M	$109.4M	$109.4M
YoY Change	277.06%	691.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.400M	$1.190M	$1.200M
YoY Change	100.0%	477.67%
Accrued Expenses	$16.30M	$10.94M	$10.90M
YoY Change	49.54%	75.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.80M	$15.32M	$15.30M
YoY Change	22.88%	5006.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.200M
YoY Change
Total Long-Term Liabilities	$2.200M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.80M	$15.32M	$15.30M
Total Long-Term Liabilities	$2.200M	$0.00	$0.00
Total Liabilities	$21.00M	$15.32M	$15.30M
YoY Change	37.25%	136.06%
SHAREHOLDERS EQUITY
Retained Earnings		-$91.23M
YoY Change		267.28%
Common Stock		$5.000K
YoY Change		25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$391.5M	$94.07M	$94.10M
YoY Change
Total Liabilities & Shareholders Equity	$412.5M	$109.4M	$109.4M
YoY Change	277.06%	691.05%

Cashflow Statement

Concept	2021	2020 Q1	2020
OPERATING ACTIVITIES
Net Income	-$107.4M	-$20.55M	-$66.39M
YoY Change	61.82%		132.13%
Depreciation, Depletion And Amortization	$65.00K	$0.00	$21.00K
YoY Change	209.52%		110.0%
Cash From Operating Activities	-$83.33M	-$23.05M	-$53.36M
YoY Change	56.17%		86.91%
INVESTING ACTIVITIES
Capital Expenditures	$210.0K	-$10.00K	$31.00K
YoY Change	577.42%		-40.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$210.0K	-$10.00K	-$31.00K
YoY Change	577.42%		-40.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$383.1M	100.0K	$147.0M
YoY Change	160.67%	-155.56%	313.03%
NET CHANGE
Cash From Operating Activities	-$83.33M	-23.05M	-$53.36M
Cash From Investing Activities	-$210.0K	-10.00K	-$31.00K
Cash From Financing Activities	$383.1M	100.0K	$147.0M
Net Change In Cash	$299.6M	-22.96M	$93.59M
YoY Change	220.11%	12655.56%	1239.81%
FREE CASH FLOW
Cash From Operating Activities	-$83.33M	-$23.05M	-$53.36M
Capital Expenditures	$210.0K	-$10.00K	$31.00K
Free Cash Flow	-$83.54M	-$23.04M	-$53.39M
YoY Change	56.47%		86.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001764013
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38906
CY2021	dei	Entity Registrant Name EntityRegistrantName	IMMUNOVANT, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2771572
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	320 West 37th Street
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	City Area Code CityAreaCode	917
CY2021	dei	Local Phone Number LocalPhoneNumber	580-3099
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	IMVT
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100571000	USD
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Public Float EntityPublicFloat	1460500000	USD
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97976695	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400146000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8312000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5460000	USD
CY2021Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	548000	USD
CY2020Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	36000	USD
CY2021Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65000	USD
CY2020Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	3009000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	409006000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	109076000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3282000	USD
CY2021Q1	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2020Q1	us-gaap	Deferred Costs DeferredCosts	246000	USD
CY2021Q1	us-gaap	Assets Assets	412489000	USD
CY2020Q1	us-gaap	Assets Assets	109387000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2432000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1190000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15160000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10938000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1179000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2020Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3190000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18771000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15318000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2238000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Liabilities Liabilities	21009000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	15318000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2020Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97971243	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97971243	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56455376	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54655376	shares
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	412489000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109387000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	66078000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	590425000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185306000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-298000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198657000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91226000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	391480000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	94069000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68604000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47927000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39513000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18151000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	108117000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	97000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	412000	USD
CY2021	us-gaap	Interest Expense InterestExpense	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-107789000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-66388000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-66291000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2020	us-gaap	Interest Expense InterestExpense	625000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	328000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.22
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87756513	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43199191	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-66388000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-282000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-362000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66750000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	7339000	USD
CY2020	imvt	Settlement Of Common Stock Subscription SettlementOfCommonStockSubscription	1000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	109772000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-282000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-362000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107713000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35587000	USD
CY2020	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	175000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6788000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-362000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-66388000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	94069000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	907000	USD
CY2021	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	184000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18638000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	933000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-282000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	391480000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-66388000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18822000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6963000	USD
CY2021	us-gaap	Depreciation Depreciation	65000	USD
CY2020	us-gaap	Depreciation Depreciation	21000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	282000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	362000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000	USD
CY2021	imvt	Gains Losses On Extinguishments Of Debts GainsLossesOnExtinguishmentsOfDebts	0	USD
CY2020	imvt	Gains Losses On Extinguishments Of Debts GainsLossesOnExtinguishmentsOfDebts	38000	USD
CY2021	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2020	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1628000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1251000	USD
CY2020	imvt	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable	96000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	967000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2852000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2824000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	512000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-13000	USD
CY2021	imvt	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable	-3009000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4468000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6502000	USD
CY2021	imvt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-798000	USD
CY2020	imvt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	244000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83327000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53357000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-210000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	USD
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1096000	USD
CY2020	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1157000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	907000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1236000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3107000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	35000000	USD
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2500000	USD
CY2021	imvt	Proceeds From Settlement Of Common Shares Subscribed ProceedsFromSettlementOfCommonSharesSubscribed	0	USD
CY2020	imvt	Proceeds From Settlement Of Common Shares Subscribed ProceedsFromSettlementOfCommonSharesSubscribed	1000	USD
CY2021	imvt	Cash Received On Recapitalization Transaction CashReceivedOnRecapitalizationTransaction	0	USD
CY2020	imvt	Cash Received On Recapitalization Transaction CashReceivedOnRecapitalizationTransaction	111016000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	383112000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	146974000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	299575000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93586000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100571000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6985000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400146000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100571000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4215000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	imvt	Purchase Of Property And Equipment In Accounts Payable PurchaseOfPropertyAndEquipmentInAccountsPayable	0	USD
CY2020	imvt	Purchase Of Property And Equipment In Accounts Payable PurchaseOfPropertyAndEquipmentInAccountsPayable	9000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	35000000	USD
CY2021	imvt	Noncash Or Part Noncash Deferred Initial Public Offering Costs Included In Accrued Expenses NoncashOrPartNoncashDeferredInitialPublicOfferingCostsIncludedInAccruedExpenses	0	USD
CY2020	imvt	Noncash Or Part Noncash Deferred Initial Public Offering Costs Included In Accrued Expenses NoncashOrPartNoncashDeferredInitialPublicOfferingCostsIncludedInAccruedExpenses	246000	USD
CY2021	imvt	Forgiveness Of Interest On Convertible Promissory Notes Recorded In Equity ForgivenessOfInterestOnConvertiblePromissoryNotesRecordedInEquity	0	USD
CY2020	imvt	Forgiveness Of Interest On Convertible Promissory Notes Recorded In Equity ForgivenessOfInterestOnConvertiblePromissoryNotesRecordedInEquity	587000	USD
CY2021	imvt	Noncash Financing Activities Total NoncashFinancingActivitiesTotal	0	USD
CY2020	imvt	Noncash Financing Activities Total NoncashFinancingActivitiesTotal	35833000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	166000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	61000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400100000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198700000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[B] Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, litigation accruals, clinical trial accruals, operating leases, research and development costs and income taxes. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact that the COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[D] Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk include cash. At March 31, 2021, the cash balance is kept in one banking institution that the Company believes is of high credit quality and is in excess of federally insured levels. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash.</span></div>
CY2021	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2021Q1	imvt	Number Of Sublease Agreements NumberOfSubleaseAgreements	3	subleaseAgreement
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9094675	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31433888	shares
CY2020Q2	imvt	Class Of Warrant Or Right Redeemed ClassOfWarrantOrRightRedeemed	11438290	shares
CY2020Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5719145	shares
CY2020Q2	imvt	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	61710	shares
CY2019Q4	imvt	Business Combination Share Price Threshold Trading Days BusinessCombinationSharePriceThresholdTradingDays	20	tradingDay
CY2019Q4	imvt	Business Combination Share Price Trading Period BusinessCombinationSharePriceTradingPeriod	30	tradingDay
CY2019Q4	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	420900000	USD
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.00
CY2019Q4	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	13.88
CY2019Q4	imvt	Business Combination Per Share Reverse Recapitalization BusinessCombinationPerShareReverseRecapitalization	10.00
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2800000	USD
CY2019Q3	imvt	Common Stock To Potential Forfeiture In The Event That The Milestones Are Not Achieved CommonStockToPotentialForfeitureInTheEventThatTheMilestonesAreNotAchieved	1800000	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1800000	shares
CY2017Q4	imvt	Upfront Payments UpfrontPayments	30000000.0	USD
CY2017Q4	imvt	Percentage Of Research And Development Costs PercentageOfResearchAndDevelopmentCosts	0.50
CY2017Q4	imvt	Milestone Payments MilestonePayments	10000000	USD
CY2018Q4	imvt	Sub Licensed Agreement Aggregate Purchase Price SubLicensedAgreementAggregatePurchasePrice	37800000	USD
CY2020Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	3000000.0	USD
CY2021Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	10147000	USD
CY2020Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	8332000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1196000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1231000	USD
CY2021Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3138000	USD
CY2020Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	859000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	679000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	516000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15160000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10938000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13921000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-107789000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-66291000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-358000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	97000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	97000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-22636000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	6662000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4255000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-363000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1303000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1093000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15427000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9988000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1581000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	951000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-439000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	713000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-83000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	97000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0033
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0015
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-400000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6597000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6445000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21865000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9443000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3623000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1610000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2790000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1487000	USD
CY2021Q1	imvt	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	698000	USD
CY2020Q1	imvt	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	0	USD
CY2020Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	187000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	214000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35787000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19172000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34953000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19129000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	834000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	43000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	42000	USD
CY2020Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	691000	USD
CY2020Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	101000	USD
CY2020Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	30000	USD
CY2021Q1	imvt	Sale Of Stock Amount Maximum Offering Price SaleOfStockAmountMaximumOfferingPrice	900000000	USD
CY2021Q1	imvt	Sale Of Stock Percentage Of Proceeds Owed Through Sales Agreement SaleOfStockPercentageOfProceedsOwedThroughSalesAgreement	0.03
CY2020Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35000000.0	USD
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1800000	shares
CY2021Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	834000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	43000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19100000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97971243	shares
CY2020Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	65800000	USD
CY2021Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2020Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7988999	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3873888	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1781043	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5283520	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5750000	shares
CY2021Q1	imvt	Earnout Shares Reserved For Issuance EarnoutSharesReservedForIssuance	0	shares
CY2020Q1	imvt	Earnout Shares Reserved For Issuance EarnoutSharesReservedForIssuance	20000000	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10875718	shares
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	34917408	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11438290	shares
CY2020Q2	imvt	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	61710	shares
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2186215	shares
CY2020Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5719145	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3873888	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M13D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28029000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4840668	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.28
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	114084	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.57
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	384407	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.14
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1130000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7988999	shares
CY2021	imvt	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod	226233	shares
CY2021	imvt	Share Based Compensation Arrangements By Share Based Payment Award Options Cancellations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice	7.86
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	833	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	24.41
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y14D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25958000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1626473	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.86
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M29D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11977000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.17
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.54
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1106626	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.67
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	10000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	44.60
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	950	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	48.85
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1095676	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	20.43
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1152000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18638000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6788000	USD
CY2020Q2	imvt	Number Of Sublease Agreements NumberOfSubleaseAgreements	2	subleaseAgreement
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4200000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4200000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.039
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	900000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1290000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	47000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3619000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	202000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3417000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1179000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2238000	USD

Files In Submission

Name	View Source	Status
0001764013-21-000052-index-headers.html	Edgar Link	pending
0001764013-21-000052-index.html	Edgar Link	pending
0001764013-21-000052.txt	Edgar Link	pending
0001764013-21-000052-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
imvt-20210331.htm	Edgar Link	pending
imvt-20210331.xsd	Edgar Link	pending
imvt-20210331xex1017.htm	Edgar Link	pending
imvt-20210331xex231.htm	Edgar Link	pending
imvt-20210331xex3111.htm	Edgar Link	pending
imvt-20210331xex3121.htm	Edgar Link	pending
imvt-20210331xex3211.htm	Edgar Link	pending
imvt-20210331xex3221.htm	Edgar Link	pending
imvt-20210331_cal.xml	Edgar Link	unprocessable
imvt-20210331_def.xml	Edgar Link	unprocessable
imvt-20210331_g1.jpg	Edgar Link	pending
imvt-20210331_g2.jpg	Edgar Link	pending
imvt-20210331_g3.jpg	Edgar Link	pending
imvt-20210331_g4.jpg	Edgar Link	pending
imvt-20210331_g5.jpg	Edgar Link	pending
imvt-20210331_g6.jpg	Edgar Link	pending
imvt-20210331_g7.jpg	Edgar Link	pending
imvt-20210331_g8.jpg	Edgar Link	pending
imvt-20210331_htm.xml	Edgar Link	completed
imvt-20210331_lab.xml	Edgar Link	unprocessable
imvt-20210331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMVT
Immunovant, Inc. Stock $imvt

2021 Form 10-K Financial Statement

#000176401321000052 Filed on June 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT Immunovant, Inc. Stock $imvt

2021 Form 10-K Financial Statement

#000176401321000052 Filed on June 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT
Immunovant, Inc. Stock $imvt